Abstract: Objective To observe and appraise the effi cacy and safety of pemetrexed and docetaxel combined with Nedaplatin respectively as the first-line therapy for patients with advanced lung adenocarcinoma . Methods Sixty-eight newly diagnosed patients with advanced lung adenocarcinoma, with physical status (PS) 0-2 were involved. Thirty four patients received nedaplatin 80 mg/m2 combined with pemetrexed 500 mg/m2. The rest of 34 patients received nedaplatin 80 mg/m2 combined with docetaxel 75 mg/m2. Results Sixty-seven patients were evaluable for effi cacy from the 68 cases. Disease control rate were 44.12 % vs. 44.12%, median survival time were 8.5 months vs. 8.2 months, and the 1-year survival rate were 30.3% vs. 26.5%, in the pemetrexed group vs. the Docetaxel group respectively. No statistically signifi cant differences were found between the two groups(P >0.05). The incidence of treatment emergent neutropenia and alopecia occurred in the observation group were signifi cantly lower than that in the control group（P＜0.05）. No signifi cant differences were found in adverse reactions, such as nausea, vomit and fatigue, of both groups （P >0.05）. Conclusion The similar efficacy were observed in Pemetrexed plus Nedaplatin group and Docetaxel plus Nedaplatin group for advanced lung adenocarcinoma. However, Pemetrexed group showed more advantages on the incidence of adverse reactions.